Citadel Advisors’s Veracyte VCYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.93M | Sell |
152,941
-6,722
| -4% | -$249K | ﹤0.01% | 4362 |
|
|
2025
Q4 | $6.72M | Sell |
159,663
-318,186
| -67% | -$12.8M | ﹤0.01% | 3838 |
|
|
2025
Q3 | $16.4M | Buy |
477,849
+11,822
| +3% | +$339K | ﹤0.01% | 2588 |
|
|
2025
Q2 | $12.6M | Buy |
466,027
+409,252
| +721% | +$11.9M | ﹤0.01% | 2726 |
|
|
2025
Q1 | $1.68M | Sell |
56,775
-239,425
| -81% | -$9.13M | ﹤0.01% | 5878 |
|
|
2024
Q4 | $11.7M | Sell |
296,200
-204,173
| -41% | -$7.73M | ﹤0.01% | 2783 |
|
|
2024
Q3 | $17M | Buy |
500,373
+452,731
| +950% | +$12.7M | ﹤0.01% | 2219 |
|
|
2024
Q2 | $1.03M | Sell |
47,642
-7,438
| -14% | -$156K | ﹤0.01% | 6516 |
|
|
2024
Q1 | $1.22M | Sell |
55,080
-649,032
| -92% | -$15.8M | ﹤0.01% | 6531 |
|
|
2023
Q4 | $19.4M | Sell |
704,112
-7,269
| -1% | -$175K | ﹤0.01% | 2052 |
|
|
2023
Q3 | $15.9M | Buy |
711,381
+503,449
| +242% | +$12.9M | ﹤0.01% | 2125 |
|
|
2023
Q2 | $5.3M | Sell |
207,932
-934,459
| -82% | -$22.7M | ﹤0.01% | 3566 |
|
|
2023
Q1 | $25.5M | Buy |
1,142,391
+591,907
| +108% | +$14.3M | 0.01% | 1688 |
|
|
2022
Q4 | $13.1M | Buy |
550,484
+144,559
| +36% | +$3.36M | ﹤0.01% | 2458 |
|
|
2022
Q3 | $6.74M | Buy |
405,925
+121,788
| +43% | +$2.74M | ﹤0.01% | 3383 |
|
|
2022
Q2 | $5.66M | Buy |
284,137
+107,769
| +61% | +$2.18M | ﹤0.01% | 3568 |
|
|
2022
Q1 | $4.86M | Buy |
176,368
+35,970
| +26% | +$1.03M | ﹤0.01% | 4226 |
|
|
2021
Q4 | $5.78M | Sell |
140,398
-115,698
| -45% | -$5.11M | ﹤0.01% | 4048 |
|
|
2021
Q3 | $11.9M | Buy |
256,096
+24,757
| +11% | +$1.08M | ﹤0.01% | 2768 |
|
|
2021
Q2 | $9.25M | Buy |
231,339
+118,122
| +104% | +$5.05M | ﹤0.01% | 3201 |
|
|
2021
Q1 | $6.08M | Buy |
113,217
+103,032
| +1,012% | +$5.93M | ﹤0.01% | 3842 |
|
|
2020
Q4 | $498K | Sell |
10,185
-86,680
| -89% | -$4.02M | ﹤0.01% | 8153 |
|
|
2020
Q3 | $3.15M | Buy |
+96,865
| New | +$3.08M | ﹤0.01% | 3905 |
|
|
2020
Q2 | – | Sell |
-18,570
| Closed | -$451K | – | 10556 |
|
|
2020
Q1 | $451K | Buy |
+18,570
| New | +$467K | ﹤0.01% | 6629 |
|
|
2019
Q4 | – | Sell |
-69,922
| Closed | -$1.68M | – | 9818 |
|
|
2019
Q3 | $1.68M | Buy |
69,922
+12,929
| +23% | +$344K | ﹤0.01% | 4772 |
|
|
2019
Q2 | $1.63M | Sell |
56,993
-152,776
| -73% | -$3.82M | ﹤0.01% | 4879 |
|
|
2019
Q1 | $5.25M | Buy |
209,769
+23,294
| +12% | +$445K | ﹤0.01% | 2935 |
|
|
2018
Q4 | $2.35M | Buy |
186,475
+81,734
| +78% | +$966K | ﹤0.01% | 3907 |
|
|
2018
Q3 | $1M | Buy |
+104,741
| New | +$1.16M | ﹤0.01% | 5545 |
|
|
2018
Q2 | – | Sell |
-11,178
| Closed | -$78.6K | – | 9325 |
|
|
2018
Q1 | $62K | Sell |
11,178
-78
| -0.7% | -$483 | ﹤0.01% | 7863 |
|
|
2017
Q4 | $74K | Buy |
+11,256
| New | +$83.7K | ﹤0.01% | 7521 |
|
|
2017
Q3 | – | Sell |
-18,036
| Closed | -$150K | – | 8091 |
|
|
2017
Q2 | $150K | Buy |
+18,036
| New | +$147K | ﹤0.01% | 6736 |
|
|
2017
Q1 | – | Sell |
-18,187
| Closed | -$149K | – | 8084 |
|
|
2016
Q4 | $141K | Buy |
+18,187
| New | +$136K | ﹤0.01% | 6536 |
|
|
2016
Q1 | – | Sell |
-15,380
| Closed | -$91K | – | 8025 |
|
|
2015
Q4 | $111K | Buy |
+15,380
| New | +$104K | ﹤0.01% | 6567 |
|
Other funds holding VCYT
VPM
VCM
AIM
Citadel Advisors's VCYT Position: Q1 2026 in Review
Citadel Advisors reduced its Veracyte (VCYT) stake by 4.2% in Q1 2026, selling an estimated $249K and leaving 152,941 shares worth $4.93M. The position accounts for ﹤0.01% of the portfolio, ranked #4362.
Citadel Advisors first reported a position in VCYT in Q4 2015 and has held it in 34 quarters since. The position peaked at $25.5M in Q1 2023. 334 funds tracked by Wall St. Rank hold VCYT as of Q1 2026.
- Citadel Advisors held 152,941 shares of Veracyte worth $4.93M as of Q1 2026.
- Citadel Advisors sold 6,722 Veracyte shares in Q1 2026, an estimated $249K.
- Veracyte made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4362 holding.
- Citadel Advisors first reported a position in Veracyte in Q4 2015 and has held it in 34 quarters since.
- Citadel Advisors's Veracyte position peaked at $25.5M in Q1 2023.
- 334 funds tracked by Wall St. Rank held Veracyte as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.